Valneva's Lyme disease vaccine candidate - VLA15

Lyme disease is the most common vector-borne illness in the Northern Hemisphere. Valneva's candidate is the only vaccine in clinical development worldwide.

Valneva reported positive Phase 1 interim data for its Lyme disease vaccine candidate VLA15 (Press release). The Company has successfully concluded the end of Phase 1 process for this candidate with the Food and Drug Administration (FDA) and has obtained alignment with regard to its Phase 2 strategy (Press release). In December 2018, Valneva announced the initiation of the Phase 2 clinical development (Press Release).

Valneva´s vaccine candidate VLA15, under Fast Track Designation by the FDA, is a multivalent vaccine that targets the outer surface protein A (OspA) of Borrelia. Pre-clinical data showed that VLA15 has the potential for protection against the majority of Borrelia species pathogenic for humans (Source).
 
The global market for a vaccine against Lyme disease is currently estimated at approximately €700 - €800 million annually1.

About Lyme disease
Lyme disease is set to explode and we still don’t have a vaccine, New Scientist, 29/03/2017
 

Additional Valneva publications on Lyme disease
18th World Vaccine Congress 2018 - Presentation on Lyme disease
PR Valneva Reports Positive Phase I Interim Results for Its Lyme vaccine candidate VLA15
PR Valneva Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15
17th World Vaccine Congress 2017 - Presentation on Lyme disease
Lyme Disease - A Tick-Transmitted Infection (brochure)
PR Valneva Receives FDA and European Approvals to Start Clinical Testing of Lyme Disease Vaccine Candidate
 
This program is supported by the Vienna Business Agency.

Wirtschaftsagentur Wien


1 Company estimate supported by independen market studies
Please update your browser...